[Tumor suppressor gene p53 and molecular targeting therapy].
Takimoto
Rishu
R
Dept of Internal Medicine IV, Sapporo Medical University.
Niitsu
Yoshiro
Y
D017209:Apoptosis; D001372:Aza Compounds / Q000494:pharmacology / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology / Q000627:therapeutic use; D053222:Fas Ligand Protein; D018390:Gene Targeting; D016158:Genes, p53; D015316:Genetic Therapy; D006801:Humans; D008562:Membrane Glycoproteins / Q000378:metabolism; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D051028:bcl-2-Associated X Protein
D001372:Aza Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D011743:Pyrimidines; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; C451219:2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one; C402665:CP 31398